Monrovia, CA, Feb. 21, 2025 (GLOBE NEWSWIRE) -- eXoZymes Inc. (NASDAQ: EXOZ, formerly Invizyne Technologies) - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into essential chemicals, medicines, and biofuels - and MDB Capital Holdings (NASDAQ: MDBH) - a premier venture platform for breakthrough technology companies - today announced key leadership changes within the eXoZymes board of directors.
Read the original post:
eXoZymes and MDB Capital Announce Leadership Transition at eXoZymes Inc.
Related Post
- NKGen Biotech Announces Administration of First Dose of Troculeucel to Frontotemporal Dementia Patient Under FDA-Cleared Compassionate Use Program - February 24th, 2025
- Ocugen to Host Conference Call on Wednesday, March 5, 2025 at 8:30 A.M. ET to Discuss Business Updates and Fourth Quarter and Full Year 2024 Financial... - February 24th, 2025
- Firefly Neuroscience Announces Exercise of Warrants for Total Proceeds of $8.8 Million - February 24th, 2025
- Neuronetics to Report Fourth Quarter 2024 Financial and Operating Results and Host Conference Call - February 24th, 2025
- Inozyme Pharma to Present Recently Announced Interim Data for INZ-701 in Infants and Young Children with ENPP1 Deficiency at CHOP Cardiology 2025 - February 24th, 2025
- Ensho Therapeutics Announces Presentation of Data Highlighting NSHO-101 as a Once-Daily Oral Agent for the Potential Treatment of Inflammatory Bowel... - February 24th, 2025
- Biostax Corp Announces Voluntary Delisting from OTC Pink Market and SEC Deregistration - February 24th, 2025
- Longeveron® to Report Full Year 2024 Financial Results and Host Conference Call on February 28, 2025 - February 24th, 2025
- Dogecoin Cash, Inc. (OTC:CBDS) Announces Strategic Expansion of Crypto Holdings with Acquisition of 420 Million Dogecoin Cash ($DOG) - February 24th, 2025
- Ipsen S.A. publishes its 2024 consolidated financial statements - February 24th, 2025
- Fortrea to Add Erin L. Russell to Board of Directors - February 24th, 2025
- Tevogen Bio’s First Trading Year Efficiency: 600% Higher Market Cap Per Team Member, 79% Insider-Owned - February 24th, 2025
- Teva and Sanofi Present New Positive Phase 2b Study Results at ECCO 2025 Reinforcing Best-in-Class Potential of Duvakitug (Anti-TL1A) in Ulcerative... - February 24th, 2025
- Dr. Gregory George MD PhD Joins Mesoblast Board - February 24th, 2025
- IO Biotech Announces New Preclinical Data for Additional Pipeline Candidate Presented at the AACR-IO Conference - February 24th, 2025
- Press Release: ECCO 2025: new duvakitug data reinforce best-in-class potential in ulcerative colitis and Crohn’s disease - February 24th, 2025
- OSE Immunotherapeutics Reports Full Phase 2 Induction Results for Anti-IL-7R mAb Lusvertikimab in Ulcerative Colitis at the 20th Congress of ECCO - February 24th, 2025
- Sandoz launches biosimilar Pyzchiva® (ustekinumab-ttwe) in the US, offering new treatment for around 12 million patients[1-4] - February 24th, 2025
- Cellectis Presents ‘Smart CAR T’ Strategy to Enhance Efficacy Against Solid Tumors at AACR-IO 2025 - February 24th, 2025
- Benitec Biopharma Announces Acceptance of Late- Breaking Oral Abstract for the BB-301 Phase 1b/2a Clinical Study at the Muscular Dystrophy Association... - February 15th, 2025
- ORYZON Announces Journal Publication of Final Phase IIa REIMAGINE Results with Vafidemstat in Psychiatry and Clinical Neurosciences - February 15th, 2025
- Outlook Therapeutics® Reports Financial Results for First Quarter Fiscal Year 2025 and Provides Corporate Update - February 15th, 2025
- Nasdaq confirms Evaxion is fully compliant, withdraws delisting determination - February 15th, 2025
- Artelo Biosciences Announces New Data on ART12.11 Tablets Showing Improved Pharmacokinetics to Epidiolex® - February 15th, 2025
- IN8bio Presents Positive Phase 1 Data at TCT 2025, Highlighting Durability of Remissions in High-Risk AML - February 15th, 2025
- Benitec Biopharma Releases Second Quarter 2025 Financial Results and Provides Operational Update - February 15th, 2025
- Longeveron to Present at the Emerging Growth Virtual Conference on February 19, 2025 - February 15th, 2025
- Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.) - February 15th, 2025
- Tevogen Bio Shares 2024 Financing Activity on One Year Anniversary of Becoming a Publicly Listed Company; Highlights Operational Efficiency - February 15th, 2025
- Tevogen Bio CEO Addresses Short Selling and Its Potential Impact on the Nation’s Health and Prosperity - February 15th, 2025
- Entero Therapeutics Appoints Richard Paolone as CEO - February 15th, 2025
- NurExone Biologic Continues Expansion of U.S. Presence and Awareness with Prestigious Conference Presentation - February 15th, 2025
- Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - February 15th, 2025
- Dyne Therapeutics Announces Upcoming Presentations at the 2025 MDA Clinical & Scientific Conference - February 15th, 2025
- Natural Alternatives International, Inc. Announces 2025 Q2 and YTD Results - February 15th, 2025
- Edesa Biotech Reports Fiscal 1st Quarter 2025 Results - February 15th, 2025
- Bavarian Nordic Receives U.S. FDA Approval of Chikungunya Vaccine for Persons Aged 12 and Older - February 15th, 2025
- Tevogen Bio CEO Reinforces Commitment to Retention of Equity Capital and Long-Term Vision - February 15th, 2025
- PacBio Grants Equity Incentive Award to New Employee - February 15th, 2025
- Rakovina Therapeutics Announces Additional Synthesized Compounds in its AI-Driven Cancer Drug Discovery Program - February 7th, 2025
- Intelligent Bio Solutions expects to achieve 32.6% Gross Profit Expansion and Increased Profitability on Higher-Margin Sales - February 7th, 2025
- Wave Life Sciences Announces Initiation of Phase 1 INLIGHT Clinical Trial of WVE-007 in Obesity - February 7th, 2025
- North Texas Took Center Stage at Advanced Therapies Week 2025, Highlighting Innovation and Collaboration in Life Sciences - February 7th, 2025
- BioAdaptives Welcomes UFC Senior Executive Reed Harris to Its Board of Advisors - February 7th, 2025
- GUERBET : 2024 revenue. - February 7th, 2025
- Denali Therapeutics Announces Primary Analysis and Long-Term Follow-Up of Phase 1/2 Study in Hunter Syndrome (MPS II) with Tividenofusp Alfa - February 7th, 2025
- Shareholding declaration Valneva SE - January 2025 - February 7th, 2025
- Ipsen - January 2025 - Monthly information relative to the total number of voting rights and shares composing the share capital - February 7th, 2025
- CARBIOS is pleased that the European Commission has authorised the ‘Circular Economy’ State aid scheme - February 7th, 2025
- 60 Degrees Pharma Announces Closing of $1.075 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - February 7th, 2025
- Fulcrum Therapeutics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference - February 7th, 2025
- Senseonics Completes CE Mark Submission for Eversense 365, World’s Longest-lasting Continuous Glucose Monitor - February 7th, 2025
- Codexis Appoints Arthur Levin, PhD, to Strategic Advisory Board - February 7th, 2025
- Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative... - February 7th, 2025
- GENFIT Outlines Anticipated New Clinical Trial Initiations, Development Milestones and Data Readouts in 2025 - February 7th, 2025
- PharmAla Signs Advisory Agreement with Mr. Matthew Azrieli - February 7th, 2025
- Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025 - February 7th, 2025
- Press Release: Execution of a share buyback agreement for up to €2 billion - February 7th, 2025
- Novo Nordisk A/S: Once-weekly Mim8 is well-tolerated and efficacious in children living with haemophilia A with and without inhibitors - February 7th, 2025
- Iovance Biotherapeutics Announces the Promotion of Raj Puri, M.D., Ph.D. to Chief Regulatory Officer - November 27th, 2024
- Acumen Pharmaceuticals to Participate in the 7th Annual Evercore ISI HealthCONx Conference - November 27th, 2024
- Tectonic Therapeutic To Present on December 3rd, 2024 at the Piper Sandler Healthcare Conference - November 27th, 2024
- Fate Therapeutics to Present at Upcoming December Investor Conferences - November 27th, 2024
- Kiniksa Pharmaceuticals to Present at 7th Annual Evercore ISI HealthCONx Conference - November 27th, 2024
- 89bio to Participate in the 7th Annual Evercore HealthCONx Conference - November 27th, 2024
- Portage Biotech Reports Results for Fiscal Quarter Ended September 30, 2024 - November 27th, 2024
- Fulcrum Therapeutics to Participate in Upcoming December Conferences - November 27th, 2024
- Orchestra BioMed to Participate in the Piper Sandler 36th Annual Healthcare Conference - November 27th, 2024
- PROCEPT BioRobotics to Present at Upcoming 36th Annual Piper Sandler Healthcare Conference on December 4, 2024 - November 27th, 2024
- Lifecore Biomedical Amends and Extends Revolving Credit Facility with BMO - November 27th, 2024
- Fortrea to Present at the Citi Global Healthcare Conference - November 27th, 2024
- NKGen Biotech Receives Notifications From Nasdaq Related to Delayed Quarterly Report and Decision of the Nasdaq Hearings Panel - November 27th, 2024
- Fortrea to Present at the Evercore HealthCONx Conference - November 27th, 2024
- ANI Pharmaceuticals to Present at 36th Annual Piper Sandler Healthcare Conference - November 27th, 2024
- Aclaris Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference - November 27th, 2024
- Supernus to Participate in the 36th Annual Piper Sandler Healthcare Conference - November 27th, 2024
- Idorsia enters into exclusive negotiations for global rights to aprocitentan - November 27th, 2024
- Novartis Kisqali® receives European Commission approval in a broad population of patients with HR+/HER2- early breast cancer at high risk of... - November 27th, 2024
- 142,701 Orion Corporation A shares converted into B shares - November 27th, 2024
- Memo Therapeutics AG Announces Last Patient Enrolled in Phase II Clinical Trial of Potravitug for Treatment of BK Viremia in Kidney Transplant... - November 3rd, 2024
Tags: